Paula Lopez-Serra

TL;DR: Even at this early stage, the transcriptional repression of miRNAs by hypermethylation of their corresponding promoter loci seems to be a common feature of all human tumors, which will have translational consequences for the management of the disease.

TL;DR: It is reported that TP53TG1 is an lncRNA that is critical for the correct response of p53 to DNA damage that undergoes cancer-specific promoter hypermethylation-associated silencing and binds to the multifaceted DNA/RNA binding protein YBX1 to prevent its nuclear localization and thus the YBx1-mediated activation of oncogenes.

TL;DR: It is found that epigenetic reactivation of TBC1D16-47KD is associated with poor clinical outcome in melanoma, while conferring greater sensitivity to BRAF and MEK inhibitors and RAB5C is identified as a new TBC 1D16 target and it is shown that it regulates EGFR in melanomas cells.

TL;DR: The presence of promoter CpG island hypermethylation-linked inactivation of DERL3 (Derlin-3) is demonstrated, a key gene in the endoplasmic reticulum-associated protein degradation pathway, in human tumours and highlights the tumour suppressor features of the gene.

TL;DR: It is reported that PCNA and DMAP1 domains in the N-terminal region of DNMT1 are sufficient to modulate E-cadherin expression in the absence of noticeable changes in DNA methylation patterns in the gene promoters involved.